InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.20
(
0.83%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
87.03
(
0.68%
)
Bitcoin
60,311.55
(
-2.77%
)
Post# of 252474
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119976
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 234681

Tuesday, 06/22/2021 3:21:31 PM

Tuesday, June 22, 2021 3:21:31 PM

Post# of 252474
BMY settles US Revlimid-patent case with another challenger—Sun Pharma—on similar terms to prior settlements—(e.g. #msg-158350306):

https://www.fiercepharma.com/manufacturing/bristol-myers-settles-sun-pharma-for-limited-revlimid-generic-launch-2022

The basic framework of these settlements is: a) the generic-drug companies who settled can launch limited quantities their Revilimid generics in the US market in 2022 (Mar 2022 for Natco [the first company to settle with BMY], somewhat later for RDY, and somewhat later for Sun Pharma); and 2) the generic-drug companies who settled can launch unlimited quantities of their Revlimid generics starting on 1/31/26.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up